van den Akker-van Marle ME - Search Results

1

Costs associated with persistent allergic rhinitis are reduced by levocetirizine.

Bousquet J, Demarteau N, Mullol J, van den Akker-van Marle ME, Van Ganse E, Bachert C; XPERT study group. Bousquet J, et al. Allergy. 2005 Jun;60(6):788-94. doi: 10.1111/j.1398-9995.2005.00820.x. Allergy. 2005. PMID: 15876309 Clinical Trial.

2

Evaluation of cost of disease: assessing the burden to society of asthma in children in the European Union.

van den Akker-van Marle ME, Bruil J, Detmar SB. van den Akker-van Marle ME, et al. Allergy. 2005 Feb;60(2):140-9. doi: 10.1111/j.1398-9995.2005.00692.x. Allergy. 2005. PMID: 15647033 Review. No abstract available.

3

Putting pharmacogenetics into practice.

Hopkins MM, Ibarreta D, Gaisser S, Enzing CM, Ryan J, Martin PA, Lewis G, Detmar S, van den Akker-van Marle ME, Hedgecoe AM, Nightingale P, Dreiling M, Hartig KJ, Vullings W, Forde T. Hopkins MM, et al. Nat Biotechnol. 2006 Apr;24(4):403-10. doi: 10.1038/nbt0406-403. Nat Biotechnol. 2006. PMID: 16601719

4

Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe.

van den Akker-van Marle ME, Gurwitz D, Detmar SB, Enzing CM, Hopkins MM, Gutierrez de Mesa E, Ibarreta D. van den Akker-van Marle ME, et al. Pharmacogenomics. 2006 Jul;7(5):783-92. doi: 10.2217/14622416.7.5.783. Pharmacogenomics. 2006. PMID: 16886902

5

Cost of rheumatic disorders in the Netherlands.

van den Akker-van Marle ME, Chorus AM, Vliet Vlieland TP, van den Hout WB. van den Akker-van Marle ME, et al. Best Pract Res Clin Rheumatol. 2012 Oct;26(5):721-31. doi: 10.1016/j.berh.2012.08.005. Best Pract Res Clin Rheumatol. 2012. PMID: 23218434 Review.

6

Economic Evaluation of Concise Cognitive Behavioural Therapy and/or Pharmacotherapy for Depressive and Anxiety Disorders.

Meuldijk D, Carlier IV, van Vliet IM, van Hemert AM, Zitman FG, van den Akker-van Marle ME. Meuldijk D, et al. J Ment Health Policy Econ. 2015 Dec;18(4):175-83. J Ment Health Policy Econ. 2015. PMID: 26729009 Clinical Trial.

7

Cost-effectiveness of newborn screening for severe combined immunodeficiency.

Van der Ploeg CPB, Blom M, Bredius RGM, van der Burg M, Schielen PCJI, Verkerk PH, Van den Akker-van Marle ME. Van der Ploeg CPB, et al. Eur J Pediatr. 2019 May;178(5):721-729. doi: 10.1007/s00431-019-03346-3. Epub 2019 Feb 25. Eur J Pediatr. 2019. PMID: 30805731

8

Leveraging the Similarities Between Cost-Effectiveness Analysis and Value-Based Healthcare.

van der Poort EKJ, van den Akker-van Marle ME, Stiggelbout AM, van den Hout WB. van der Poort EKJ, et al. Value Health. 2022 Jun;25(6):1057-1058. doi: 10.1016/j.jval.2021.08.016. Epub 2022 Feb 13. Value Health. 2022. PMID: 35172952 Free article. No abstract available.

9

Implementation of a cost-effective strategy to prevent neonatal early-onset group B haemolytic streptococcus disease in the Netherlands.

Kolkman DG, Rijnders ME, Wouters MG, van den Akker-van Marle ME, van der Ploeg CK, de Groot CJ, Fleuren MA. Kolkman DG, et al. BMC Pregnancy Childbirth. 2013 Jul 30;13:155. doi: 10.1186/1471-2393-13-155. BMC Pregnancy Childbirth. 2013. PMID: 23899463 Free PMC article.

10

Domains of quality of life: results of a three-stage Delphi consensus procedure among patients, family of patients, clinicians, scientists and the general public.

Pietersma S, de Vries M, van den Akker-van Marle ME. Pietersma S, et al. Qual Life Res. 2014 Jun;23(5):1543-56. doi: 10.1007/s11136-013-0578-3. Epub 2013 Nov 17. Qual Life Res. 2014. PMID: 24241818 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

116 results

Search Page

Filters